Parallel Advisors, LLC Uni Qure N.V. Transaction History

Parallel Advisors, LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 May 20, 2024	BUY	$6.71 - $11.83 $0 - $0	0 New	0 $0
Q3 2023 Nov 13, 2023	BUY	$6.71 - $11.83 $0 - $0	0 New	0 $0
Q2 2022 Aug 01, 2022	SELL	$13.15 - $20.45 $78 - $122	-6 Closed	0 $0
Q1 2022 Apr 28, 2022	BUY	$14.54 - $21.5 $87 - $129	6 New	6 $0
Q4 2021 Jan 20, 2022	SELL	$20.24 - $36.01 $3,096 - $5,509	-153 Closed	0 $0
Q3 2021 Nov 02, 2021	BUY	$26.01 - $38.22 $3,979 - $5,847	153 New	153 $5,000
Q2 2020 Jul 16, 2020	SELL	$45.06 - $67.74 $14,689 - $22,083	-326 Closed	0 $0
Q4 2019 Jan 30, 2020	BUY	$37.13 - $74.62 $12,104 - $24,326	326 New	326 $23,000

142

35.3M

1.54M

389K

Ticker QURE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,729,100
Market Cap $300M
Description
uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy th...

Get notified when there are updates to the investment portfolio of Parallel Advisors, LLC, based on Form 13F filings with the SEC.

Stay updated on Parallel Advisors, LLC with notifications on news.